ijms-logo

Journal Browser

Journal Browser

Virus Engineering and Applications

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Microbiology".

Deadline for manuscript submissions: closed (15 April 2023) | Viewed by 19391

Special Issue Editor


E-Mail Website
Guest Editor
Department of Pharmacy and Biotechnology, University of Bologna, 40126 Bologna, Italy
Interests: oncolytic herpes simplex virus; tropism retargeting; cancer receptors; virus engineering; virus arming; virus-mediated transgene expression
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

The recent SARS-CoV-2 pandemic recalled and focused worldwide attention, perception and awareness on viruses, and highlighted the global need for preparedness to future emerging threats. At present, this is just the most exposed facet of the virus world. But viruses are much more. Virus engineering is a well-established discipline, both as a tool and as research subject, and it is now reviving thanks to the intersection with novel expanding omic breakthroughs. Thus, the possibility to retrieve viral sequences from the most diverse matrices expanded the boundaries of the virosphere in an unprecedented way. Virus engineering comes here into play, allowing to study the biological properties of viral entities, or just parts thereof, that have not been isolated as particles, or whose host is not known, with tremendous implications both in ecology and global health. Virus engineering allows to revive both known extinct or unknown possible pathogens, variants of concern, etc., and design and devise countermeasures, drugs, or vaccines, with a constant eye on the ethics and safety issues. Virus engineering allows to shed light on virus origin, emergence, and evolution, as well. Finally, an ever-growing body of knowledge builds up for increasingly sophisticated viruses engineered as therapeutic platforms themselves, for gene therapy, oncolytic virotherapy or bio-nanomaterials. In this regard, submissions of original research papers, perspectives and reviews are welcome for this Special Issue. Topics of interest include, but are not limited to:

  • basic virology;
  • viral biotechnology;
  • virus engineering platforms, toolboxes, and technologies;
  • viral vaccine platforms;
  • viral gene therapy;
  • oncolytic virotherapy and immunovirotherapy;
  • personalized medicine with virus-based biologicals;
  • ethics of virus engineering;
  • virus origin, emergence, and evolution;
  • viral synthetic biology;
  • virus metagenomics and the virosphere;
  • virus-based bio-nanomaterials and bio-nanotechnologies.

Dr. Laura Menotti
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • virus engineering
  • oncolytic virotherapy
  • immunovirotherapy
  • viral biotechnology

Related Special Issue

Published Papers (9 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Editorial

Jump to: Research, Review

3 pages, 162 KiB  
Editorial
Virus Engineering and Applications
by Laura Menotti
Int. J. Mol. Sci. 2023, 24(23), 16788; https://doi.org/10.3390/ijms242316788 - 27 Nov 2023
Viewed by 771
Abstract
This Special Issue highlights multiple facets of virus engineering, ranging from the dissection of the biological properties of individual viral functions in the context of safe genomic backbones, virus genetic modification for applications in gene therapy, oncolytic virotherapy and vaccine production, to the [...] Read more.
This Special Issue highlights multiple facets of virus engineering, ranging from the dissection of the biological properties of individual viral functions in the context of safe genomic backbones, virus genetic modification for applications in gene therapy, oncolytic virotherapy and vaccine production, to the hurdles presented by quality control and the delivery of viruses for their final applications and finally to the simulation, prediction and validation of virus evolution [...] Full article
(This article belongs to the Special Issue Virus Engineering and Applications)

Research

Jump to: Editorial, Review

15 pages, 2051 KiB  
Article
Extending AAV Packaging Cargo through Dual Co-Transduction: Efficient Protein Trans-Splicing at Low Vector Doses
by Mariana V. Ferreira, Sofia Fernandes, Ana Isabel Almeida, Salomé Neto, João P. Mendes, Ricardo J. S. Silva, Cristina Peixoto and Ana Sofia Coroadinha
Int. J. Mol. Sci. 2023, 24(13), 10524; https://doi.org/10.3390/ijms241310524 - 23 Jun 2023
Viewed by 1827
Abstract
Adeno-associated viral (AAV) vectors represent one of the leading platforms for gene delivery. Nevertheless, their small packaging capacity restricts their use for diseases requiring large-gene delivery. To overcome this, dual-AAV vector systems that rely on protein trans-splicing were developed, with the split-intein Npu [...] Read more.
Adeno-associated viral (AAV) vectors represent one of the leading platforms for gene delivery. Nevertheless, their small packaging capacity restricts their use for diseases requiring large-gene delivery. To overcome this, dual-AAV vector systems that rely on protein trans-splicing were developed, with the split-intein Npu DnaE among the most-used. However, the reconstitution efficiency of Npu DnaE is still insufficient, requiring higher vector doses. In this work, two split-inteins, Cfa and Gp41-1, with reportedly superior trans-splicing were evaluated in comparison with Npu DnaE by transient transfections and dual-AAV in vitro co-transductions. Both Cfa and Gp41-1 split-inteins enabled reconstitution rates that were over two-fold higher than Npu DnaE and 100% of protein reconstitution. The impact of different vector preparation qualities in split-intein performances was also evaluated in co-transduction assays. Higher-quality preparations increased split-inteins’ performances by three-fold when compared to low-quality preparations (60–75% vs. 20–30% full particles, respectively). Low-quality vector preparations were observed to limit split-gene reconstitutions by inhibiting co-transduction. We show that combining superior split-inteins with higher-quality vector preparations allowed vector doses to be decreased while maintaining high trans-splicing rates. These results show the potential of more-efficient protein-trans-splicing strategies in dual-AAV vector co-transduction, allowing the extension of its use to the delivery of larger therapeutic genes. Full article
(This article belongs to the Special Issue Virus Engineering and Applications)
Show Figures

Graphical abstract

19 pages, 8915 KiB  
Article
Human Monocytes Are Suitable Carriers for the Delivery of Oncolytic Herpes Simplex Virus Type 1 In Vitro and in a Chicken Embryo Chorioallantoic Membrane Model of Cancer
by Alberto Reale, Lea Krutzke, Massimiliano Cadamuro, Adriana Vitiello, Jens von Einem, Stefan Kochanek, Giorgio Palù, Cristina Parolin and Arianna Calistri
Int. J. Mol. Sci. 2023, 24(11), 9255; https://doi.org/10.3390/ijms24119255 - 25 May 2023
Cited by 1 | Viewed by 1592
Abstract
Oncolytic viruses (OVs) are promising therapeutics for tumors with a poor prognosis. An OV based on herpes simplex virus type 1 (oHSV-1), talimogene laherparepvec (T-VEC), has been recently approved by the Food and Drug Administration (FDA) and by the European Medicines Agency (EMA) [...] Read more.
Oncolytic viruses (OVs) are promising therapeutics for tumors with a poor prognosis. An OV based on herpes simplex virus type 1 (oHSV-1), talimogene laherparepvec (T-VEC), has been recently approved by the Food and Drug Administration (FDA) and by the European Medicines Agency (EMA) for the treatment of unresectable melanoma. T-VEC, like most OVs, is administered via intratumoral injection, underlining the unresolved problem of the systemic delivery of the oncolytic agent for the treatment of metastases and deep-seated tumors. To address this drawback, cells with a tropism for tumors can be loaded ex vivo with OVs and used as carriers for systemic oncolytic virotherapy. Here, we evaluated human monocytes as carrier cells for a prototype oHSV-1 with a similar genetic backbone as T-VEC. Many tumors specifically recruit monocytes from the bloodstream, and autologous monocytes can be obtained from peripheral blood. We demonstrate here that oHSV-1-loaded primary human monocytes migrated in vitro towards epithelial cancer cells of different origin. Moreover, human monocytic leukemia cells selectively delivered oHSV-1 to human head-and-neck xenograft tumors grown on the chorioallantoic membrane (CAM) of fertilized chicken eggs after intravascular injection. Thus, our work shows that monocytes are promising carriers for the delivery of oHSV-1s in vivo, deserving further investigation in animal models. Full article
(This article belongs to the Special Issue Virus Engineering and Applications)
Show Figures

Figure 1

22 pages, 3752 KiB  
Article
Exploring FeLV-Gag-Based VLPs as a New Vaccine Platform—Analysis of Production and Immunogenicity
by Raquel Ortiz, Ana Barajas, Anna Pons-Grífols, Benjamin Trinité, Ferran Tarrés-Freixas, Carla Rovirosa, Victor Urrea, Antonio Barreiro, Anna Gonzalez-Tendero, Maria Cardona, Laura Ferrer, Bonaventura Clotet, Jorge Carrillo, Carmen Aguilar-Gurrieri and Julià Blanco
Int. J. Mol. Sci. 2023, 24(10), 9025; https://doi.org/10.3390/ijms24109025 - 19 May 2023
Cited by 3 | Viewed by 1753
Abstract
Feline leukemia virus (FeLV) is one of the most prevalent infectious diseases in domestic cats. Although different commercial vaccines are available, none of them provides full protection. Thus, efforts to design a more efficient vaccine are needed. Our group has successfully engineered HIV-1 [...] Read more.
Feline leukemia virus (FeLV) is one of the most prevalent infectious diseases in domestic cats. Although different commercial vaccines are available, none of them provides full protection. Thus, efforts to design a more efficient vaccine are needed. Our group has successfully engineered HIV-1 Gag-based VLPs that induce a potent and functional immune response against the HIV-1 transmembrane protein gp41. Here, we propose to use this concept to generate FeLV-Gag-based VLPs as a novel vaccine strategy against this retrovirus. By analogy to our HIV-1 platform, a fragment of the FeLV transmembrane p15E protein was exposed on FeLV-Gag-based VLPs. After optimization of Gag sequences, the immunogenicity of the selected candidates was evaluated in C57BL/6 and BALB/c mice, showing strong cellular and humoral responses to Gag but failing to generate anti-p15E antibodies. Altogether, this study not only tests the versatility of the enveloped VLP-based vaccine platform but also sheds light on FeLV vaccine research. Full article
(This article belongs to the Special Issue Virus Engineering and Applications)
Show Figures

Figure 1

17 pages, 2241 KiB  
Article
Engineering an Optimal Y280-Lineage H9N2 Vaccine Strain by Tuning PB2 Activity
by Se-Hee An, Seung-Min Hong, Jin-Ha Song, Seung-Eun Son, Chung-Young Lee, Kang-Seuk Choi and Hyuk-Joon Kwon
Int. J. Mol. Sci. 2023, 24(10), 8840; https://doi.org/10.3390/ijms24108840 - 16 May 2023
Cited by 1 | Viewed by 1555
Abstract
H9N2 avian influenza A viruses (AIVs) cause economic losses in the poultry industry and provide internal genomic segments for the evolution of H5N1 and H7N9 AIVs into more detrimental strains for poultry and humans. In addition to the endemic Y439/Korea-lineage H9N2 viruses, the [...] Read more.
H9N2 avian influenza A viruses (AIVs) cause economic losses in the poultry industry and provide internal genomic segments for the evolution of H5N1 and H7N9 AIVs into more detrimental strains for poultry and humans. In addition to the endemic Y439/Korea-lineage H9N2 viruses, the Y280-lineage spread to Korea since 2020. Conventional recombinant H9N2 vaccine strains, which bear mammalian pathogenic internal genomes of the PR8 strain, are pathogenic in BALB/c mice. To reduce the mammalian pathogenicity of the vaccine strains, the PR8 PB2 was replaced with the non-pathogenic and highly productive PB2 of the H9N2 vaccine strain 01310CE20. However, the 01310CE20 PB2 did not coordinate well with the hemagglutinin (HA) and neuraminidase (NA) of the Korean Y280-lineage strain, resulting in a 10-fold lower virus titer compared to the PR8 PB2. To increase the virus titer, the 01310CE20 PB2 was mutated (I66M-I109V-I133V) to enhance the polymerase trimer integrity with PB1 and PA, which restored the decreased virus titer without causing mouse pathogenicity. The reverse mutation (L226Q) of HA, which was believed to decrease mammalian pathogenicity by reducing mammalian receptor affinity, was verified to increase mouse pathogenicity and change antigenicity. The monovalent Y280-lineage oil emulsion vaccine produced high antibody titers for homologous antigens but undetectable titers for heterologous (Y439/Korea-lineage) antigens. However, this defect was corrected by the bivalent vaccine. Therefore, the balance of polymerase and HA/NA activities can be achieved by fine-tuning PB2 activity, and a bivalent vaccine may be more effective in controlling concurrent H9N2 viruses with different antigenicities. Full article
(This article belongs to the Special Issue Virus Engineering and Applications)
Show Figures

Figure 1

15 pages, 2006 KiB  
Article
Boosting the Separation of Adeno-Associated Virus Capsid Proteins by Liquid Chromatography and Capillary Electrophoresis Approaches
by Megane K. Aebischer, Thomas Bouvarel, Emmalyn Barrozo, Dominik Kochardt, Carsten Elger, Markus Haindl, Raphael Ruppert, Davy Guillarme and Valentina D’Atri
Int. J. Mol. Sci. 2023, 24(10), 8503; https://doi.org/10.3390/ijms24108503 - 9 May 2023
Cited by 3 | Viewed by 2479
Abstract
The purity of the three capsid proteins that make up recombinant adeno-associated virus (rAAV) is considered a critical quality attribute of gene therapy products. As such, there is a clear need to develop separation methods capable of rapidly characterizing these three viral proteins [...] Read more.
The purity of the three capsid proteins that make up recombinant adeno-associated virus (rAAV) is considered a critical quality attribute of gene therapy products. As such, there is a clear need to develop separation methods capable of rapidly characterizing these three viral proteins (VPs). In this study, the potential benefits and limitations of different electrophoretic and chromatographic methods were evaluated, including capillary electrophoresis–sodium dodecyl sulfate (CE-SDS), reversed phase liquid chromatography (RPLC), hydrophilic interaction chromatography (HILIC), and hydrophobic interaction chromatography (HIC), for the analysis of VPs obtained from different serotypes (i.e., AAV2, AAV5, AAV8, and AAV9). CE-SDS is considered to be the reference method and provides a suitable separation of VP1-3 proteins using generic conditions and laser induced fluorescence detection. However, the characterization of post-translational modifications (i.e., phosphorylation, oxidation) remains difficult, and species identification is almost impossible due to the lack of compatibility between CE-SDS and mass spectrometry (MS). In contrast, RPLC and HILIC were found to be less generic than CE-SDS and require tedious optimization of the gradient conditions for each AAV serotype. However, these two chromatographic approaches are inherently compatible with MS, and were shown to be particularly sensitive in detecting capsid protein variants resulting from different post-translational modifications. Finally, despite being non-denaturing, HIC offers disappointing performance for viral capsid proteins characterization. Full article
(This article belongs to the Special Issue Virus Engineering and Applications)
Show Figures

Graphical abstract

13 pages, 3974 KiB  
Article
Analysis of SARS-CoV-2 Spike Protein Variants with Recombinant Reporter Viruses Created from a Bacmid System
by Arne Cordsmeier, Doris Jungnickl, Alexandra Herrmann, Klaus Korn and Armin Ensser
Int. J. Mol. Sci. 2023, 24(9), 8156; https://doi.org/10.3390/ijms24098156 - 2 May 2023
Cited by 1 | Viewed by 1407
Abstract
SARS-CoV-2, the causative agent of COVID-19, has spread around the world with more than 700 million cases and 6.8 million deaths. Various variants of concern (VoC) have emerged due to mutations and recombination and concurrent selection for increased viral fitness and immune evasion. [...] Read more.
SARS-CoV-2, the causative agent of COVID-19, has spread around the world with more than 700 million cases and 6.8 million deaths. Various variants of concern (VoC) have emerged due to mutations and recombination and concurrent selection for increased viral fitness and immune evasion. The viral protein that primarily determines the pathogenicity, infectivity, and transmissibility is the Spike protein. To analyze the specific impact of variant Spike proteins on infection dynamics, we constructed SARS-CoV-2 with a uniform B.1 backbone but with alternative Spike proteins. In addition, ORF6 was replaced by EYFP as a biological safety measure, and for use of this well-established reporter. We show that namely the delta variant Spike proteins cause a distinct phenotype from the wild type (B.1, D614G) and other variants of concern. Furthermore, we demonstrate that the omicron BA.1 Spike results in lower viral loads and a less efficient spread in vitro. Finally, we utilized viruses with the two different reporters EYFP and mCherry to establish a competitive growth assay, demonstrating that most but not all Spike variant viruses were able to outcompete wild type SARS-CoV-2 B.1. Full article
(This article belongs to the Special Issue Virus Engineering and Applications)
Show Figures

Figure 1

16 pages, 587 KiB  
Article
Quantifying In-Host Quasispecies Evolution
by Josep Gregori, Marta Ibañez-Lligoña and Josep Quer
Int. J. Mol. Sci. 2023, 24(2), 1301; https://doi.org/10.3390/ijms24021301 - 9 Jan 2023
Cited by 2 | Viewed by 1385
Abstract
What takes decades, centuries or millennia to happen with a natural ecosystem, it takes only days, weeks or months with a replicating viral quasispecies in a host, especially when under treatment. Some methods to quantify the evolution of a quasispecies are introduced and [...] Read more.
What takes decades, centuries or millennia to happen with a natural ecosystem, it takes only days, weeks or months with a replicating viral quasispecies in a host, especially when under treatment. Some methods to quantify the evolution of a quasispecies are introduced and discussed, along with simple simulated examples to help in the interpretation and understanding of the results. The proposed methods treat the molecules in a quasispecies as individuals of competing species in an ecosystem, where the haplotypes are the competing species, and the ecosystem is the quasispecies in a host, and the evolution of the system is quantified by monitoring changes in haplotype frequencies. The correlation between the proposed indices is also discussed, and the R code used to generate the simulations, the data and the plots is provided. The virtues of the proposed indices are finally shown on a clinical case. Full article
(This article belongs to the Special Issue Virus Engineering and Applications)
Show Figures

Figure 1

Review

Jump to: Editorial, Research

21 pages, 1297 KiB  
Review
Viral Vector-Based Gene Therapy
by Xuedan Li, Yang Le, Zhegang Zhang, Xuanxuan Nian, Bo Liu and Xiaoming Yang
Int. J. Mol. Sci. 2023, 24(9), 7736; https://doi.org/10.3390/ijms24097736 - 23 Apr 2023
Cited by 14 | Viewed by 5868
Abstract
Gene therapy is a technique involving the modification of an individual’s genes for treating a particular disease. The key to effective gene therapy is an efficient carrier delivery system. Viral vectors that have been artificially modified to lose their pathogenicity are used widely [...] Read more.
Gene therapy is a technique involving the modification of an individual’s genes for treating a particular disease. The key to effective gene therapy is an efficient carrier delivery system. Viral vectors that have been artificially modified to lose their pathogenicity are used widely as a delivery system, with the key advantages of their natural high transduction efficiency and stable expression. With decades of development, viral vector-based gene therapies have achieved promising clinical outcomes. Currently, the three key vector strategies are based on adeno-associated viruses, adenoviruses, and lentiviruses. However, certain challenges, such as immunotoxicity and “off-target”, continue to exist. In the present review, the above three viral vectors are discussed along with their respective therapeutic applications. In addition, the major translational challenges encountered in viral vector-based gene therapies are summarized, and the possible strategies to address these challenges are also discussed. Full article
(This article belongs to the Special Issue Virus Engineering and Applications)
Show Figures

Figure 1

Back to TopTop